Document:

Payment
Rights Certificate No. PAR-[●]

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY STATE SECURITIES LAWS. THESE SECURITIES, AND ANY INTEREST THEREIN, MAY NOT BE OFFERED, SOLD, ASSIGNED, OR OTHERWISE TRANSFERRED
UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS,
OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES,
WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED
IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

Effective
Date: December 22, 2016

 

MOTUS
GI HOLDINGS, INC.

 

PAYMENT
RIGHTS CERTIFICATE

 

Motus
GI Holdings, Inc., a Delaware corporation (the “Company”), for value received on December 22, 2016 (the
“Effective Date”), hereby issues to [●] (the “Certificate Holder”) this Payment Rights
Certificate (the “Certificate”) to receive [●]% of the aggregate Royalty Amount payable from time to
time to the Holders of the Royalty Payment Rights (the “Certificate Payment”). This Certificate is one of a
series of payment right certificates of like tenor that have been issued to the Placement Agent or its designees (the “Placement
Agent Royalty Payment Rights Certificates”) in connection with the Company’s private offering of securities pursuant
to the terms of that certain Confidential Private Placement Memorandum of the Company dated December 1, 2016, as the same may
have been amended and supplemented from time to time, and the Placement Agency Agreement dated December 1, 2016, as the same may
have been amended from time to time. The Placement Agent Royalty Payment Rights Certificates provide for an aggregate payment
to all holders of such Placement Agent Royalty Payment Rights Certificates equal to 10% of the aggregate Royalty Amount paid from
time to time to the Holders of the Royalty Payment Rights. All capitalized terms used but not otherwise defined herein shall have
the meaning ascribed to such terms in Exhibit A, attached hereto.

 

1.
DURATION OF CERTIFICATE

 

(a)
Timing of Payments to Certificate Holder. The Certificate Holder will be entitled to receive the Certificate Payments at
the same time and in the same fashion as payments are made to the Holders of the Royalty Payment Rights, as described in Section
(c) of Exhibit A, attached hereto.

 

(b)
Royalty Period. This Certificate shall become void and of no value upon the expiration of the Royalty Term.

 

    	 

    	 

    

 

2.
ISSUANCE OF CERTIFICATE

 

The
Company shall register this Certificate upon records to be maintained by the Company for that purpose in the name of the record
holder of such Certificate from time to time. The Company may deem and treat the registered Certificate Holder of this Certificate
as the absolute owner thereof for the purpose of any Certificate Payments to the Certificate Holder thereof and for all other
purposes.

 

3.
TRANSFERS AND EXCHANGES OF CERTIFICATE

 

(a)
Registration of Transfers and Exchanges. Subject to Section 3(b), upon the Certificate Holder’s surrender of this
Certificate, with a duly executed copy of the Form of Assignment attached as Exhibit B and a written opinion of
legal counsel addressed to the Company that the proposed transfer of the Certificate may be effected without registration under
the Securities Act, which opinion will be in form and from counsel reasonably satisfactory to the Company, to the Secretary of
the Company at its principal offices or at such other office or agency as the Company may specify in writing to the Certificate
Holder, the Company shall register the transfer of all or any portion of this Certificate. Upon such registration of transfer,
the Company shall issue a new Certificate, in substantially the form of this Certificate, evidencing the acquisition rights transferred
to the transferee and a new Certificate, in similar form, evidencing the remaining acquisition rights not transferred, to the
Certificate Holder requesting the transfer.

 

(b)
Certificate Exchangeable for Different Denominations. The Certificate Holder may exchange this Certificate for a new Certificate
or Certificates, in substantially the form of this Certificate, evidencing in the aggregate the right to receive the Certificate
Payment which may then be received hereunder, each of such new Certificates to be dated the date of such exchange and to represent
the right to receive such percentage of Certificate Payments as shall be designated by the Certificate Holder. The Certificate
Holder shall surrender this Certificate with duly executed instructions regarding such re-certification of this Certificate to
the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify in writing
to the Certificate Holder.

 

(c)
Restrictions on Transfers. This Certificate may not be transferred at any time without (i) registration under the Securities
Act of 1933, as amended (the “Securities Act”) or (ii) an exemption from such registration and a written opinion
of legal counsel addressed to the Company that the proposed transfer of the Certificate may be effected without registration under
the Securities Act, which opinion will be in form and from counsel reasonably satisfactory to the Company.

 

(d)
Permitted Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 3, the Certificate Holder
may transfer, with or without consideration, this Certificate (or a portion thereof) to the Certificate Holder’s Affiliates
(as such term is defined under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required
by Section 3(c)(ii), provided, that the Certificate Holder delivers to the Company and its counsel certification, documentation,
and other assurances reasonably required by the Company’s counsel to enable the Company’s counsel to render an opinion
to the Company’s Transfer Agent that such transfer does not violate applicable securities laws.

 

    	-2- 

    	 

    

 

4.
MUTILATED OR MISSING CERTIFICATE

 

If
this Certificate is mutilated, lost, stolen or destroyed, upon request by the Certificate Holder, the Company will, at its expense,
issue, in exchange for and upon cancellation of the mutilated Certificate, or in substitution for the lost, stolen or destroyed
Certificate, a new Certificate, in substantially the form of this Certificate, representing the right to acquire the equivalent
amount of Certificate Payments; provided, that, as a prerequisite to the issuance of a substitute Certificate, the Company
may require satisfactory evidence of loss, theft or destruction as well as an indemnity from the Certificate Holder of a lost,
stolen or destroyed Certificate.

 

5.
NO RIGHTS IN COMPANY’S SECURITIES

 

No
holder of this Certificate, as such, shall be entitled to vote or be deemed the holder of any other securities of the Company,
nor shall anything contained herein be construed to confer upon the holder of this Certificate, as such, the rights of a stockholder
of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders at any meeting
thereof, or give or withhold consent to any corporate action or to receive notice of meetings or other actions affecting stockholders
(except as provided herein), or to receive dividends or subscription rights or otherwise.

 

6.
NOTICES

 

All
notices, consents, waivers, and other communications under this Certificate must be in writing and will be deemed given to a party
when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b)
sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee,
if sent by certified mail, return receipt requested, if to the registered Certificate Holder hereof; or (d) seven days after the
placement of the notice into the mails (first class postage prepaid), to the Certificate Holder at the address, facsimile number,
or e-mail address furnished by the registered Certificate Holder to the Company, or if to the Company, to it at 150 Union Square
Drive, New Hope, PA 18938, Attn: James Martin, CFO (or to such other address, facsimile number, or e-mail address as the Certificate
Holder or the Company as a party may designate by notice to the other party).

 

    	-3- 

    	 

    

 

7.
SEVERABILITY

 

If
a court of competent jurisdiction holds any provision of this Certificate invalid or unenforceable, the other provisions of this
Certificate will remain in full force and effect. Any provision of this Certificate held invalid or unenforceable only in part
or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

8.
BINDING EFFECT

 

This
Certificate shall be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the
registered Certificate Holder or Certificate Holders from time to time of this Certificate.

 

9.
GOVERNING LAW

 

This
Certificate will be governed by and construed under the laws of the State of New York without regard to conflicts of laws principles
that would require the application of any other law.

 

10.
DISPUTE RESOLUTION

 

In
the case of a dispute as to the arithmetic calculation of the Royalty Amount and/or the Certificate Payment, the Company shall
submit the disputed arithmetic calculation(s) via facsimile within two Business Days of receipt of a written notice from the Certificate
Holder giving rise to such dispute, to the Certificate Holder. If the Certificate Holder and the Company are unable to agree upon
such calculation of the Royalty Amount and/or the Certificate Payment within three Business Days of such disputed arithmetic calculation
being submitted to the Certificate Holder, then the Company shall, within two Business Days, submit via facsimile the disputed
arithmetic calculation of the Royalty Amount and/or the Certificate Payment to the Company’s independent, outside accountant.
The Company shall cause at its expense the accountant to perform the calculation(s) and notify the Company and the Certificate
Holder of the results no later than ten (10) Business Days from the time it receives the disputed arithmetic calculation(s). Such
accountant’s calculation(s) shall be binding upon all parties absent demonstrable error.

 

11.
NO THIRD PARTY RIGHTS

 

This
Certificate is not intended, and will not be construed, to create any rights in any parties other than the Company and the Certificate
Holder, and no person or entity may assert any rights as third-party beneficiary hereunder.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	-4- 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Certificate to be duly executed as of the date first set forth above.

 

MOTUS
GI HOLDINGS, INC.  

 

	By:
    	 	 
	Name:
    	 	 
	Title:
    	 	 

 

[Signature
Page to Placement Agent Royalty Payment Rights Certificate]

 

    	 

    	 

    

 

EXHIBIT
A

 

ROYALTY
PAYMENT RIGHTS

 

The
Holders of the Series A Convertible Preferred Stock of Motus GI Holdings, Inc. (the “Company”) have
the royalty payment rights (the “Royalty Payment Rights”), as set forth in and subject to the terms
and conditions of the Company’s Certificate of Designation, and as reproduced in this Exhibit A to this Payment
Rights Certificate. Upon the Mandatory Conversion Date, any Holder of the Series A Convertible Preferred Stock will no longer
be entitled to Royalty Payment Rights by virtue of owning shares of Series A Convertible Preferred Stock and instead the Company
shall issue to each Holder a Royalty Payment Rights certificate, evidencing such Royalty Payment Rights, which certificate shall
contain in all material respects the Royalty Payment Rights set forth in the Company’s Certificate of Designation.

 

Section
(a) Definitions. For purposes of this Exhibit A, the following terms have the following meanings:

 

“Affiliate”
means any person controlled directly or indirectly through one or more intermediaries, by the Company. A Person shall be regarded
as in control of the Company if the Company owns or directly or indirectly controls more than fifty percent (50%) of the voting
stock or other ownership interest of the other person, or if it possesses, directly or indirectly, the power to direct or cause
the direction of the management and policies of such person.

 

“Business
Day” means any day except Saturday, Sunday, and any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.

 

“Certificate
of Designation” means the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series
A Convertible Preferred Stock, as filed with the Secretary of State of the State of Delaware on December 20, 2016.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, including any securities issued or issuable
with respect thereto or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend,
stock split, stock combination, recapitalization, reclassification, reorganization or other similar event

 

“Company
Conversion Notice” means a notice delivered by the Company to effect a Mandatory Conversion of all the outstanding
Series A Convertible Preferred Stock, provided that the effective date of such Mandatory Conversion shall be no less than ten
Business Days following delivery of such notice.

 

“Conversion
Price” means $5.00, subject to adjustment as set forth in the Certificate of Designation.

 

“First
Commercial Sale” means, on a country by country basis, with respect to a Product, the first bona fide sale
of such Product to a third party by or on behalf of the Company or its Affiliates in a country after Regulatory Approval has been
achieved for such Product in such country. For greater certainty, sales for test marketing, sampling and promotional uses, clinical
trial purposes or compassionate or similar use shall not be considered to constitute a First Commercial Sale, so long as the Product
is provided free of charge, or at or below cost.

 

    	- Exhibit A-1-

    	 

    

 

“Holder”
shall mean the owner of the Series A Convertible Preferred Stock.

 

“Investor”
mean the holder of Participating Royalty Interests.

 

“Licensing
Proceeds” means all cash received by the Company and its Affiliates from third party licensees or partners with
respect to licensing or partnering arrangements with respect to a Product, including, without limitation, (i) royalties based
on sales of Products by third party licensees or their sublicensees; (ii) any licensing fees (including, without limitation, upfront
fees) for rights to develop or commercialize Products, or other payments in connection with the licensing of rights with respect
to Products; (iii) milestone payments (including without limitation, those based on development, regulatory or commercialization
milestones for Products); and (iv) research and development funding.

 

“Mandatory
Conversion” means the event, on the Mandatory Conversion Date, pursuant to which each outstanding share of Series
A Convertible Preferred Stock will automatically convert into such number of fully paid and non-assessable shares of Common Stock
as is determined by dividing the Stated Value by the Conversion Price in effect on the Mandatory Conversion Date.

 

“Mandatory
Conversion Date” means the sooner to occur of (i) December 19, 2019 or (ii) the effective date set forth in the
Company Conversion Notice.

 

“Net
Sales” means for any period, the gross amount invoiced by the Company and its Affiliates for the sale of Products,
(including, without limitation, third party agents, distributors and wholesalers), less the total of the following, to the extent
applicable:

 

	 	(i)	trade,
    cash and/or quantity discounts not already reflected in the amount invoiced;
	 	 	 
	 	(ii)	all
    excise, sales and other consumption taxes (including VAT) and custom duties, whether or not specifically identified as such
    in the invoice to the third party;
	 	 	 
	 	(iii)	freight,
    distribution, insurance and other transportation charges, whether or not specifically identified as such in the invoice to
    the third party;
	 	 	 
	 	(iv)	amounts
    repaid or credited by reason of rejections, defects or returns or because of chargebacks, retroactive price reductions, refunds
    or billing errors;
	 	 	 
	 	(v)	any
    royalty amounts or license fees payable by the Company to a non-Affiliate third party for access to, or licensing in of, such
    non-Affiliate third party’s intellectual property rights for use or exploitation of the Products; and
	 	 	 
	 	(vi)	rebates
    and similar payments made with respect to sales paid for or reimbursed by any governmental or regulatory authority such as,
    by way of illustration, United States Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental
    program.

 

    	- Exhibit A-2-

    	 

    

 

For
purposes of determining Net Sales, “sale” will not include transfers or dispositions for charitable, promotional,
pre-clinical, clinical, regulatory or governmental purposes. “Net Sales” also excludes all Licensing Proceeds received
by the Company and its Affiliates from third party licensees to the extent that a royalty payment has otherwise been made with
respect to such Licensing Proceeds.

 

“Participating
Royalty Interests” shall mean (i) for each Holder the number of shares of Series A Convertible Preferred Stock held
on the applicable Record Date, and (ii) for all Holders in the aggregate the number of shares of Series A Convertible Preferred
Stock held by all Holders on the applicable Record Date.

 

“Patent”
shall mean all national, regional, and international (a) issued patents, including without limitation utility patents,
design patents, and utility models; (b) pending patent applications (whether provisional or non-provisional); (c) divisionals,
continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations of any of the foregoing,
and patents resulting from any opposition or post-grant proceedings, including without limitation post-grant review, covered business
method patent review, inter partes review, and derivation proceedings; and (d) any other forms of governmental authority issued
rights substantially similar to any of the foregoing.

 

“Person”
means an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership,
joint-stock company, trust or unincorporated organization.

 

“Preferred
Stock” means the Company’s preferred stock, par value $0.0001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed into.

 

“Private
Placement Offering” means only that private placement offering of Units conducted pursuant to the Confidential Private
Placement Memorandum of the Company, dated November 30, 2016.

 

“Product”
means either (i) the Pure-Vu system, including disposables, parts, and services or (ii) any other system or device that is covered
by a Patent issued to or issuable to the Company as of December 20, 2016 (the date the Company’s Certificate of Designation
was filed with the Secretary of State of the State of Delaware).

 

“Record
Date” means the third Business Day prior to the applicable date, as determined in Section (c) of this Exhibit A,
on which a Royalty Amount is payable by the Company.

 

“Regulatory
Approval” means the approval of the Company’s Pure-Vu system product candidate by the U.S. Food and Drug
Administration or the European Medicines Agency.

 

“Royalty
Amount” shall have the meaning set forth in Section (b) of this Exhibit A.

 

    	- Exhibit A-3-

    	 

    

 

“Royalty
Amount Per Share” shall be expressed as a dollar amount and shall be equal to the Royalty Amount divided by the
aggregate Participating Royalty Interests on the applicable Record Date.

 

“Royalty
Term” means, with respect to each Product, on a country by country basis in each country, commencing on the First
Commercial Sale of the Product, if the Company is commercializing the Product directly, or the date the Company enters into a
licensing agreement or partnering agreement for such Product until the last of:

 

	 	(i)	the
    expiration of the last to expire of the Valid Claims covering such Product in such country; or
	 	 	 
	 	(ii)	the
    expiration of any regulatory exclusivity period covering such Product in such country.

 

For
clarity, by way of example, the Royalty Term in the United States extends to October 2026 as of the effective date of the Certificate
of Designation, which period may be altered by the prosecution of the Company’s patent claims and new patent filings from
time-to-time.

 

“Series
A Convertible Preferred Stock” means the series of Preferred Stock, $0.0001 par value per share, designated by the
Company’s Certificate of Designation, as filed with the Secretary of State of the State of Delaware on December 20, 2016.

 

“Stated
Value” means $5.00 per share.

 

“Units”
means the units consisting of (i) three-quarter (3/4) of a share of Common Stock, and (ii) one-quarter (1/4) a share of Series
A Convertible Preferred Stock offered pursuant to the Private Placement Offering.

 

“Valid
Claim” means a claim (i) of an issued and unexpired United States Patent that has not been revoked or held permanently
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through re-issue or disclaimer
or otherwise, or (ii) of any patent application included that has not been cancelled, withdrawn or abandoned or been pending for
more than six (6) years.

 

Section
(b) Royalties. During the Royalty Term, the Company will pay to the Holders, with the allocation between Holders determined
as set forth in Section (e) of this Exhibit A, in aggregate, a royalty in an amount (referred to as the “Royalty Amount”)
equal to:

 

	Company Commercializes
    Product Directly	 	The Rights to Commercialize
    the Product is Sublicensed by Company to a third-party
	3.0% of Net Sales, subject in all cases for
    all Products in any calendar year up to $30,000,000.	 	5.0% of any Licensing Proceeds, subject in all
    cases for all Products in any calendar year up to $30,000,000.

 

    	- Exhibit A-4-

    	 

    

 

Section
(c) Timing of Royalty Payments. With respect to Products that the Company commercializes directly, royalty payments, if
any, will be paid annually 15 Business Days after the issuance of the Company’s audited financial statements for the prior
year. With respect to Products that the Company sublicenses or otherwise disposes of to a third-party, royalty payments, if any,
will be paid 10 business days after the end of the applicable quarter in which such Licensing Proceeds were received by the Company.
However, all royalty payments shall be accrued by the Company until 15 Business Days after the issuance of the Company’s
audited financial statements for the earlier of (i) the calendar year in which Net Sales exceed $15 million or Licensing Proceeds
exceed $2.5 million, or (ii) the year ended December 31, 2019, at which time all accrued royalties shall be paid in a lump sum
along with the regular royalty payments and subsequent royalty payments will be made irrespective of the amount of annual Net
Sales or Licensing Proceeds.

 

Section
(d) Vesting. The shares of Series A Convertible Preferred Stock will be immediately vested upon issuance. If a Holder elects
to convert all of its Series A Convertible Preferred Stock into Common Stock, pursuant to Section (a) of this Exhibit A, prior
to the Mandatory Conversion Date, the Holder will forfeit any and all rights to future Royalty Payment Rights, if any. If a Holder
elects to convert a portion but not all of its Series A Convertible Preferred Stock into Common Stock at any time prior to the
Mandatory Conversion Date, such Holder will forfeit any rights to future Royalty Payment Rights, if any, with respect to such
converted shares.

 

Section
(e) Allocation of Royalty Payment. Once the Royalty Amount has been calculated as set forth in Section (b) of this Exhibit
A, the royalty payable to each Investor shall be calculated as follows:

 

(i)
Prior to the three year anniversary of the effective date of the Certificate of Designation, the royalty payable to each Investor
will be equal to the Royalty Amount Per Share multiplied by the number of Participating Royalty Interests held by Investor
on the applicable Record Date

 

(ii)
On or after the three year anniversary of the effective date of the Certificate of Designation, the royalty payable to each Investor
will be calculated by multiplying the Royalty Amount by the percentage set forth in each Investor’s Royalty Payment Rights
certificate. The percentage set forth in each Royalty Payment Rights certificate will be calculated as follows:

 

	Number
    of Participating Royalty Interests Held by Investor after the three year anniversary of the effective date of the Certificate
    of Designation
	Total Participating
    Royalty Interests after the three year anniversary of the effective date of the Certificate of Designation

 

Section
(f) Separability/Effect of Transfer. The Royalty Payment Rights may not be transferred separate from the shares of Series
A Convertible Preferred Stock until after the three year anniversary of the effective date of the Certificate of Designation.
Upon the three year anniversary of the effective date of the Certificate of Designation, the Company will issue a certificate
representing the Royalty Payment Rights to each Holder of shares of Series A Convertible Preferred Stock at such date. Such Royalty
Payment Rights certificate shall set forth the applicable percentage of any Royalty Amounts payable by the Company on or after
the date of issuance of such Royalty Payment Rights certificate and the other applicable terms for such Royalty Payment Rights.
Following the issuance of Royalty Payment Rights certificate, the Holders of shares of Series A Convertible Preferred Stock will
not have any Royalty Payment Rights resulting from their ownership of such shares of Series A Convertible Preferred Stock and
the Royalty Payment Rights shall soley be evidenced by the Royalty Payment Rights certificate and may be transferred, subject
to the availability of an exemption from registration under applicable state and federal securities laws, separately from the
shares of Series A Convertible Preferred Stock. For all transfers made prior to the three year anniversary of effective date of
the Certificate of Designation, the Royalty Payment Rights will follow any transfer of the shares of Series A Convertible Preferred
Stock. If a Holder transfers any of its shares of Series A Convertible Preferred Stock prior to the three year anniversary of
the effective date of the Certificate of Designation, the transferee of such shares will have thereafter the Royalty Payment Rights
related to the shares of Series A Convertible Preferred Stock it receives, and the transferring Holder will thereafter no longer
have any Royalty Payment Rights in respect of the shares of Series A Convertible Preferred Stock it transferred.

 

Section
(g) Unsecured Obligations. The Royalty Payment Rights are unsecured obligations of the Company.

 

Section
(h) Amendments, Modifications and Waivers. Prior to the Mandatory Conversion Date, all modifications, amendments or waivers
to the Royalty Payment Rights shall require the written consent of the Company and the Holders of the majority of the then outstanding
shares of Series A Convertible Preferred Stock. Following the issuance of the Royalty Payment Rights certificate, all modifications,
amendments or waivers to the Royalty Payment Rights shall require the written consent of the Company and the holders of Royalty
Payment Rights certificates representing, in the aggregate, the right to receive at least 50% of any Royalty Amount payable by
the Company.

 

    	- Exhibit A-5-

    	 

    

 

EXHIBIT
B

 

FORM
OF ASSIGNMENT

 

FOR
VALUE RECEIVED, ___________________________________ hereby sells, assigns and transfers to each assignee set forth below all of
the rights of the undersigned under the Certificate (as defined in and evidenced by the attached Certificate) to acquire the percentage
of the Certificate Payment set opposite the name of such assignee below and in and to the foregoing Certificate with respect to
said acquisition rights:

 

	Name
    of Assignee	 	Address	 	Certificate
    Payment Percentage
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

If
the total above does not represent all of the Certificate Payment evidenced by the foregoing Certificate, the undersigned requests
that a new Certificate evidencing the right to acquire the remaining portion of the Certificate Payment not so assigned by issued
in the name of and delivered to the undersigned.

 

Name
of Holder (print): _____________________________

(Signature):_______________________________________

	 	(By:)	 
	 	(Title:)	 
	 	Dated:Employment
Agreement

 

This
Employment Agreement (“Agreement”), dated August 16, 2017 and effective as of the Commencement Date (as defined
below), is entered into between Motus GI Medical Technologies Ltd., a Delaware corporation, having its corporate headquarters
at 1301 East Broward Blvd, Fort Lauderdale, Florida (“Company”), and Andrew Taylor, an individual residing
at 816 Winter Road, Rydal, PA 19046 (“Executive”) (Company and Executive, each a “Party”
and together, the “Parties”).

 

WHEREAS,
Company desires to employ Executive as its Chief Financial Officer; and

 

WHEREAS,
Executive is willing to accept such employment on the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements set forth herein, Company and Executive hereby agree as follows:

 

ARTICLE
I

EMPLOYMENT;
POSITION, DUTIES AND RESPONSIBILITIES

 

1.01       Employment
and Acceptance. Company agrees to, and does hereby, employ Executive, and Executive agrees to, and does hereby accept, such
employment, upon the terms and subject to the conditions set forth in this Agreement.

 

1.02       Position,
Duties and Responsibilities. During the Term (as defined in Section 2.01 below), Executive shall serve as Chief Financial
Officer of Company as well as in such other positions or capacities as may be reasonably requested by the Board of Directors of
Company (the “Board”) or the Chief Executive Officer of Company (the “CEO”) and shall have
such duties and responsibilities as are customary for, and are consistent with, such position(s) as may, from time to time, be
assigned by the Board, the CEO and/or any of their respective nominees. Executive’s employment by Company shall be full-time
and exclusive to Company and Executive shall (a) report to Company’s CEO, (b) comply with Company’s policies and procedures
in place from time to time, and (c) serve Company faithfully and to the best of Executive’s ability. During the Term, and
except for paid time off in accordance with the terms of Section 3.01(G) below or absences due to illness or incapacity, Executive
shall devote all of Executive’s business time, attention, skill and efforts exclusively to the business and affairs of Company
(including its affiliates) and the promotion of its interests. Notwithstanding anything contained herein to the contrary, Executive
may do the following, provided that such activities do not inhibit or prohibit the performance of Executive’s duties hereunder
or inhibit or conflict with the business of Company and/or its affiliates: (i) engage in charitable, educational, religious, civic
and similar types of activities and manage Executive’s personal investments, and (ii) with consent of the Board which shall
not be unreasonably withheld, serve on the board of directors, managers, advisors (or their equivalent) of outside business enterprises
for up to 30 hours in the aggregate per calendar quarter (including but not limited to AngelMed, GenPro, and eNeura). Executive
shall be required to spend on average eight days per month at the Company’s corporate offices in either Florida or Israel
including travel. Executive acknowledges that he shall be required to travel as reasonably necessary to perform Executive’s
duties hereunder, including international travel.

 

    	 

    	 

    

 

ARTICLE
II

TERM

 

2.01       Term
of Employment. Executive’s employment under this Agreement shall commence on August 16, 2017 (the “Commencement
Date”) and shall continue for two years, unless terminated sooner by either Company or Executive pursuant to Article
IV hereof. The Term shall thereafter be deemed to be automatically extended, upon the same terms and conditions, for successive
periods of one year, unless either Party, at least one hundred twenty (120) days prior to the expiration of the original term
or any extended term, shall give written notice to the other of its intention not to renew such employment term. The period during
which Executive is employed pursuant to this Agreement, including any extension thereof in accordance with the preceding sentence,
shall be referred to as the “Term.” It is understood and agreed that, for purposes of this Agreement, the non-renewal
of this Agreement by either party shall not be deemed to be a termination of Executive’s employment hereunder without “Cause”
(as defined below).

 

ARTICLE
III

COMPENSATION
AND BENEFITS; EXPENSES

 

3.01       Compensation
and Benefits. For all services rendered by Executive in any capacity during the Term (including, without limitation, serving
as an officer, director or member of any committee of Company or any affiliate or division thereof), Executive shall be compensated
as follows (subject, in each case, to the provisions of Article IV below):

 

(A)       Base
Salary. During the Term, Company shall pay to Executive a base salary at the initial rate of $295,000 on an annualized basis
(the “Base Salary”). As used in this Agreement, the term “Base Salary” shall refer to Base
Salary as may be adjusted from time to time with the consent of the Company and the Executive. Base Salary shall be payable in
accordance with the customary payroll practices of Company.

 

(B)       Starting
Bonus. Executive shall be eligible to receive a starting bonus of $15,000.00 payable on the next regular paydate following
the six month anniversary of the Commencement Date, provided Executive is actively employed in good standing on such date.

 

(C)       Relocation
Bonus. The Company agrees to reimburse the Executive for reasonable and customary expenses that the Executive incurs through
the twenty-fourth month anniversary of the Commencement Date, in an amount up to $35,000, if Executive elects to relocate to Florida
and upon presentation of receipts associated with Executive’s relocation to Florida.

 

    	 	-2-	 

    	 

    

 

(D)       First
Year Bonus. Executive shall be eligible to receive a bonus of up to $30,000.00 payable on the next regular paydate following
the one year anniversary of the Commencement Date (the “First Year Bonus”), provided Executive is actively
employed in good standing on such date. Seventy percent (70%) of the First Year Bonus shall be based upon the Company’s
determination of whether the Company has achieved certain designated milestones (such milestones to be communicated to Executive
in advance of the Commencement Date) and thirty percent (30%) of the First Year Bonus shall be based upon the Company’s
assessment of the Executive’s performance, as determined in the Board’s discretion and judgment.

 

(E)       Second
Year Bonus. Executive shall be eligible to receive a bonus of up to $35,000.00 payable on the next regular paydate following
the two year anniversary of the Commencement Date (the “Second Year Bonus”), provided Executive is actively
employed in good standing on such date. Seventy percent (70%) of the Second Year Bonus shall be based upon the Company’s
determination of whether the Company has achieved certain designated milestones (such milestones to be communicated to Executive
in advance of Second Year) and thirty percent (30%) of the Second Year Bonus shall be based upon the Company’s assessment
of the Executive’s performance, as determined in the Board’s discretion and judgment.

 

(F)       Equity
Compensation. Pursuant to the terms of the Company’s Equity Incentive Plan (the “Plan”), Executive
shall, as soon as reasonably practicable after the Commencement Date, be granted an option (the “Option”) to
purchase 240,000 shares of the Company’s common stock (the “Common Stock”). The Option shall vest equally
over three (3) years on a quarterly basis. The exercise price of the Option will be equal to the fair market value of the Common
Stock on the date of grant, as determined by the Board in a manner consistent with Section 409A of the Code. The Option will be
governed by a stock option agreement to be entered into between Executive and the Company pursuant to the Plan. Thereafter during
the Term, Executive shall be eligible to receive from time to time stock option grants and/or restricted stock awards pursuant
to the Plan in amounts, if any, to be approved by the Board or the Compensation Committee in its discretion. Such grants or awards
will be subject to the terms and conditions established within the Plan (or any successor equity compensation plan as may be in
place from time to time) and separate stock option and/or restricted stock award agreements between Company and Executive that
sets forth the terms of the award or grant. If there is a Change of Control, the Company agrees that all outstanding unvested
equity options or rights granted to the Executive during the Term shall become fully vested and exercisable for the remainder
of their full term. A “Change in Control” shall mean the consummation of any one of the following events: (a)
a sale, lease, transfer or other disposition of all or substantially all of the assets of the Company; (b) a consolidation or
merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in
which the stockholders of the Company immediately prior to such consolidation, merger or reorganization, own less than fifty percent
(50%) of the Company’s outstanding voting power of the surviving entity following the consolidation, merger or reorganization;
(c) any transaction (or series of related transactions involving a person or entity, or a group of affiliate persons or entities)
in which in excess of fifty percent (50%) of the Company’s then outstanding voting power is transferred, excluding any consolidation
or merger, effected exclusively to change the domicile of the Company and excluding any such change of voting power resulting
from a bona fide equity financial event or public offering of the stock of the Company.

 

    	 	-3-	 

    	 

    

 

(G)       Benefits.
During the Term, Executive shall be entitled to participate in all Executive benefit plans and programs (excluding severance plans,
if any) generally made available by Company to Executives of Company, to the extent permissible under the general terms and provisions
of such plans or programs and in accordance with the provisions thereof. Company may amend, modify or rescind any employee benefit
plan or program and/or change employee contribution amounts to benefit costs without notice in its discretion. Executive’s
eligibility for severance shall be governed by the terms of this Agreement.

 

(H)       Paid
Time Off (PTO). During the Term, Executive shall be entitled to paid time off in accordance with Company’s policy in
place from time to time; provided, however, that Executive shall be eligible to accrue no less than twenty (20) days per
calendar year (with such amount prorated for the balance of 2017).

 

3.02       Expenses.
Executive shall be entitled to receive reimbursement from Company for reasonable out-of-pocket expenses incurred by Executive
during the Term in connection with the performance of Executive’s duties and obligations under this Agreement, according
to Company’s expense account and reimbursement policies in place from time to time and provided that Executive shall submit
reasonable documentation with respect to such expenses; provided, however, in no event shall a reimbursement be made later
than December 31 of the year following the year in which the expense was incurred. For purposes of clarity, notwithstanding the
Company’s expense account and reimbursement policies, Executive is permitted to travel by air in business class or equivalent
if the trip is international and if flight time (one-way) of such international trip is greater than six hours. Further, for all
air, lodging, ground transportation and related expenses associated with Executive’s business travel, Executive is eligible
to retain in his own personal account all points, mileage and equivalent affinity benefits associated with that travel.

 

ARTICLE
IV

TERMINATION

 

4.01       Events
of Termination. This Agreement and Executive’s employment hereunder shall terminate upon the occurrence of any one or
more of the following events:

 

(A)       Death.
In the event of Executive’s death, this Agreement and Executive’s employment hereunder shall automatically terminate
on the date of death.

 

(B)       Disability.
To the extent permitted by law, in the event of Executive’s physical or mental disability that prevents Executive from performing
the essential functions of Executive’s duties under this Agreement (with or without reasonable accommodation) for a period
of at least ninety (90) consecutive days in any 12-month period or one hundred twenty (120) non-consecutive days in any 12-month
period, Company may terminate this Agreement and Executive’s employment hereunder upon giving written notice of termination
to Executive.

 

    	 	-4-	 

    	 

    

 

(C)       Termination
by Company for Cause. Company may, at its option, terminate this Agreement and Executive’s employment hereunder for
Cause (as defined below) upon giving notice of termination to Executive. As used in this Agreement, “Cause”
shall mean the termination of the Executive’s employment because of:

 

(1)       gross
negligence or willful misconduct in the performance of the Executive’s duties hereunder, or if the Executive otherwise breaches
this Agreement;

 

(2)       the
Executive’s failure to obey a lawful directive that is from the CEO or the Board, which failure is not cured within 15 days
written notice of the alleged failure to perform;

 

(3)       a
material violation of the restrictive covenants described in Article V below or of any written employee conduct policy of the
Company against workplace harassment or discrimination); or

 

(4)       conviction
of a felony or other serious crime; or

 

(5)       any
other act or omission that results in material harm to the business, reputation of the Company.

 

(D)       Without
Cause by Company. Company may, at its option, at any time terminate this Agreement and Executive’s employment hereunder
for no reason or for any reason whatsoever (other than for Cause or as a result of Executive’s death or Disability) by giving
written notice of termination to Executive.

 

(E)       Termination
by Executive. Executive may terminate this Agreement and Executive’s employment hereunder with or without Good Reason
(as defined below) by: (i) in the case of a resignation without Good Reason, giving thirty (30) days prior written notice of termination
to Company; or (ii) in the case of a resignation for Good Reason, giving written notice of resignation within thirty (30) days
after the expiration of the Good Reason Cure Period; provided, however, in each case, Company reserves the right, upon
written notice to Executive, to accept Executive’s notice of resignation and to accelerate such notice and make Executive’s
resignation effective immediately, or on such other date prior to Executive’s intended last day of work as Executive deems
appropriate. The Company’s election to accelerate Executive’s notice of resignation shall not be deemed a termination
by Company. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following circumstances
without Executive’s prior express written consent: (i) a material adverse change in the nature of Executive’s title,
duties or responsibilities with the Company that represents a material demotion from his title, duties or responsibilities as
in effect immediately prior to such change; (ii) a material breach of this Agreement by the Company; (iii) a failure by the Company
to make any payments to Executive when due, unless the payment is not material and is being contested by the Company, in good
faith; (iv) the Company’s performance of any illegal or civilly actionable act that materially damages Executive’s
reputation or is considered harassment under applicable law; (v) any material reduction of the Executive’s then current
annual Base Salary except to the extent that the annual Base Salary of all other similarly situated employees of the Company or
its successor is similarly reduced; (vi) any requirement that the Executive relocate to a work site that is more than fifty miles
from his home; or (vii) a liquidation, bankruptcy or receivership of the Company. Notwithstanding the foregoing, no Good Reason
shall be deemed to exist with respect to the Company’s acts described in clause (i) above, unless Executive shall have given
written notice to the company specifying the Good Reason with reasonable particularity within (ninety) 90 days after the date
Executive first knew or should reasonably have known of the occurrence of any such event and, within fifteen (15) days after such
notice, the Company shall not have cured or eliminated the problem or thing giving rise to such Good Reason; provided,
however, that a repeated breach after notice and cure of any provision of clause (i) above involving the same or substantially
similar actions or conduct, shall be grounds for termination for Good Reason without any additional notice from Executive. If
Executive fails to provide the notice and Good Reason Cure Period prior to Executive’s resignation, or resigns more than
ninety (90) days after the initial existence of the condition, Executive’s resignation will not be deemed to be for “Good
Reason” and any claim of such circumstances as “Good Reason” shall be deemed irrevocably waived by Executive.

 

    	 	-5-	 

    	 

    

 

(F)       Mutual
Agreement. This Agreement and Executive’s employment hereunder may be terminated at any time by the mutual agreement
of Company and Executive.

 

4.02       Company’s
Obligations upon Termination.

 

(A)
Termination by Company for Cause; Termination by Executive without Good Reason; Mutual Agreement; Death; Disability. In
the event of a termination of this Agreement and Executive’s employment hereunder pursuant to Sections 4.01(A), 4.01(B),
4.01(C), 4.01(E) (other than a termination for Good Reason), or 4.01(F) above, then this Agreement and Executive’s employment
with Company shall terminate and Company’s sole obligation to Executive (or Executive’s estate, heirs, executors,
administrators, representatives and assigns) under this Agreement or otherwise shall be to: (i) pay to Executive (or, if applicable,
Executive’s estate) any Base Salary earned, but not yet paid, prior to the effective date of such termination, payable in
accordance with Company’s standard payroll practices; (ii) reimburse Executive (or, if applicable, Executive’s estate)
for any expenses incurred by Executive through the effective date of such termination in accordance with Section 3.02 above; and
(iii) pay and/or provide any amounts or benefits that are vested amounts or vested benefits or that Executive is otherwise entitled
to receive under any plan, program, policy or practice (with the exception of those, if any, relating to severance) on the date
of termination, in accordance with such plan, program, policy, or practice (including payment for unused, accrued vacation) (clauses
(i), (ii) and (iii) of this sentence are collectively referred to herein as the “Accrued Obligations”).

 

(B)
       Termination by Company without Cause; Termination by Executive for Good Reason.
In the event of a termination of this Agreement and Executive’s employment hereunder by Company pursuant to Section 4.01(D)
or a termination of this Agreement and Executive’s employment hereunder by Executive for Good Reason (as defined in Section
4.01(E) above) pursuant to Section 4.01(E), then this Agreement and Executive’s employment with Company shall terminate
and Company’s sole obligation to Executive under this Agreement or other otherwise shall be to: (i) pay and/or provide,
as applicable, the Accrued Obligations in accordance with the terms set forth in Section 4.02(A) above; and (ii) subject to Section
4.02(C) below, and provided Executive has been actively employed in good standing for at least 91 days from the Commencement Date
(a) pay to Executive an aggregate amount equal to the Severance Payment (as defined below), (b) if Executive timely elects COBRA
coverage, Company shall pay the Company portion of Executive’s healthcare continuation payments under COBRA for a twelve
(12)-month period following the date of Executive’s termination of employment with Company during which time Executive shall
be responsible for the Executive portion (unless Executive becomes eligible to obtain healthcare coverage from a new Company before
the 12-month anniversary of the termination of Executive’s employment, in which case Company’s obligation to contribute
to Executive’s health care continuation payments under COBRA shall cease), and (c) the Company agrees to accelerate the
vesting of any options that otherwise would have vested on the last day of the calendar quarter during which the termination date
occurred. Executive acknowledges that he is obligated to inform Company if Executive obtains new employment or becomes eligible
to obtain healthcare coverage from an alternate source before the twelve (12)-month anniversary of Executive’s termination
of employment.

 

    	 	-6-	 

    	 

    

 

As
used in this Section 4.02(B), the term “Severance Payment” shall mean the following: (x) zero dollars if Executive
has been employed by the Company for less than 91 days; (y) continuation of Executive’s regular Base Salary for six months,
if, on the termination date, Executive has been actively employed in good standing with the Company for at least 91 days and up
to eighteen months; and (z) continuation of Executive’s regular Base Salary for nine months if, on the termination date,
Executive has been actively employed in good standing with the Company for at least eighteen months, with all amounts offset by
any subsequent salary or consulting fees that the Executive receives from any alternate source during the applicable severance
period. Subject to Section 4.02(E) below, the Severance Payment (less applicable withholdings and customary payroll deductions,
excluding 401(k) contributions) shall be payable in equal installments in accordance with Company’s customary payroll practices,
commencing on the next regular pay date following the date that the Release (as defined in Section 4.02(D) below) becomes effective
and is no longer subject to revocation; provided, however, the first payment shall include the cumulative amount of payments
that would have been paid to Executive during the period of time between the effective date of termination and the actual commencement
date of such payments had such payments commenced immediately following the effective date of Executive’s termination.

 

Notwithstanding
anything set forth in this Section 4.02(B) to the contrary, in the event of a breach by Executive under Article V of this Agreement
or the Release and in addition to any other remedies hereunder, the Release or at law or in equity, Company’s obligation
to make any remaining installments of the Severance Payment or to contribute to Executive’s health care continuation payments
under COBRA through the 12-month anniversary of the date of termination shall terminate as of the date of such breach and Company
shall have no further obligations under this Section 4.02(B) other than to pay/provide the Accrued Obligations (to the extent
not previously paid/provided) and Executive shall be required, upon demand, to return to Company fifty percent (50%) of the Severance
Payment (or installments thereof) paid by the Company pursuant to this Section 4.02(B).

 

    	 	-7-	 

    	 

    

 

(C)       Release.
With the exception of Accrued Obligations, all payments and benefits to Executive pursuant to this Section 4.02 (including the
Severance Payment and the contribution to the Company portion of Executive’s healthcare continuation payments under COBRA)
shall be contingent upon Executive’s execution, delivery within 21 days (or 45 days in the case of a group termination)
following receipt by Executive, and non-revocation of a general release in a form satisfactory to Company (the “Release”).
The Release will be delivered to Executive within ten (10) business days following the effective date of Executive’s termination
and will include, without limitation, a general release from all liability of Company, its affiliates and each of their respective
officers, directors, shareholders, partners, managers, agents, Executives and other related parties. Notwithstanding anything
to the contrary contained herein, in the event that any payment hereunder is contingent upon Executive’s execution and delivery
of the Release and the 21 (or 45 day) period covers more than one calendar year, the payment shall be paid in the second calendar
year (on the first regular pay date of such calendar year following the date that the Release becomes effective and is no longer
subject to revocation, all subject to Section 4.02(D) below), regardless of whether the Executive executes and delivers the Release
in the first or the second calendar year encompassed in such 21 (or 45) day period.

 

(D)       Specified
Employee. If the Executive is a “specified employee” within the meaning of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”) at the time of the Executive’s termination of employment,
amounts or benefits (including the Severance Payments) that are deferred compensation subject to Section 409A of the Code, as
determined in the reasonable discretion of the Company, that would otherwise be payable or provided during the six month period
immediately following the termination of employment will instead be paid or provided, with interest on any delayed payment at
the short-term applicable federal rate under Section 1274(d) of the Code (with monthly compounding and at the rate published for
the month prior to the month in which the Executive’s termination of employment occurs), on the first business day after
the date that is six months following the Executive’s termination of employment.

 

(E)       Removal
from any Positions. If Executive’s employment is terminated for any reason under this Agreement, Executive shall be
deemed to resign from any position with Company or any affiliate of Company, including, but not limited to, as an officer of Company
or any of its affiliates.

 

ARTICLE
V

CONFIDENTIALITY,
NONCOMPETITION, NONSOLICITATION AND OTHER COVENANTS

 

5.01       Confidentiality.
Executive shall be provided with access to Confidential Information relating to the Company, its business, potential business
or that of its clients and customers. “Confidential Information” includes all trade secrets, know-how, show-how,
theories, technical, operating, financial, and other business information, whether or not reduced to writing or other medium and
whether or not marked or labeled confidential, proprietary or the like, specifically including, but not limited to, information
regarding source codes, software programs, computer systems, concepts, creations, costs, plans, materials, enhancements, research,
specifications, works of authorship, techniques, documentation, models and systems, sales and pricing techniques, designs, inventions,
discoveries, products, improvements, modifications, methodology, processes, concepts, records, files, memoranda, reports, plans,
proposals, price lists, product development and project procedures. Confidential Information does not include general skills,
experience or information that is generally available to the public, other than information which has become generally available
as a result of Executive’s direct or indirect act or omission. With respect to Confidential Information of the Company and
its clients and customers:

 

    	 	-8-	 

    	 

    

 

(A)       Executive
will use Confidential Information only in the performance of Executive’s duties for Company. Executive will not use Confidential
Information at any time (during or after Executive’s employment with Company) for Executive’s personal benefit, for
the benefit of any other individual or entity, or in any manner adverse to the interests of Company and its clients and customers
except to the extent permitted by applicable law, including to enable Executive to exercise any protected legal right he may have;

 

(B)       Executive
will not disclose Confidential Information at any time (during or after Executive’s employment with Company) except to authorized
Company personnel, unless Company consents in advance in writing or unless the Confidential Information indisputably becomes of
public knowledge or enters the public domain (other than through Executive’s direct or indirect act or omission) or as authorized
by a court or regulatory agency.

 

(C)       Executive
will safeguard the Confidential Information by all reasonable steps and abide by all policies and procedures of Company in effect
from time to time regarding storage, copying, destroying, and handling of documents; and

 

(D)       Executive
will return or destroy all materials, models, software, prototypes and the like containing and/or relating to Confidential Information,
together with all other property of Company and its clients and customers, to Company when Executive’s employment relationship
with Company terminates or otherwise on demand and, at that time Executive will certify to Company, in writing and under oath,
that Executive has complied with this Agreement. Executive shall not retain any copies or reproductions of correspondence, memoranda,
reports, notebooks, drawings, photographs, databases, diskettes, or other documents or electronically stored information of any
kind relating in any way to the business, potential business or affairs of Company and its clients and customers.

 

(E)       Executive acknowledges receipt of the following notice under the Defend Trade Secrets Act: An individual will not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret if he/she (i) makes such disclosure
in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney and such disclosure
is made solely for the purpose of reporting or investigating a suspected violation of law; or (ii) such disclosure was made in
a complaint or other document filed in a lawsuit or other proceeding if such filing is made under seal.

 

    	 	-9-	 

    	 

    

 

5.02       Obligations
to Other Persons. Executive does not have any non-disclosure or other obligations to any other individual or entity (including
without limitation, any previous Company) concerning proprietary or confidential information that Executive learned of during
any previous employment or associations that would conflict with the Executive’s obligations to Company under this Agreement.
Executive shall not disclose to Company or induce Company to use any secret or confidential information or material belonging
to others, including, without limitation, Executive’s former employers, if any. Executive does not have any non-competition
agreements, non-solicitation agreements or other restrictive covenants with any previous Company or other individual or entity
that would conflict with the Executive’s obligations to Company under this Agreement.

 

5.03       Covenants
Against Competition and Solicitation.

 

Executive
acknowledges and understands that, Executive’s position with Company affords Executive extensive access to Confidential
Information of the Company. Executive therefore agrees that during the course of Executive’s employment with Company and
for twelve (12) months after termination of Executive’s employment with Company (for any reason or no reason) (collectively,
“Restricted Period”), Executive shall not: (i) anywhere within the United States of America or any other country
in which the Company then conducts or proposes to conduct business, either directly or indirectly, as an owner, stockholder, member,
partner, joint venturer, officer, director, consultant, independent contractor, agent or Executive, engage in any business or
other commercial activity which is engaged in or is seeking to engage in a “Competitive Business.” As used in this
Agreement, “Competitive Business” shall mean any individual or enterprise engaged in (x) cleansing of body
cavities, tubular structures or other orafices or devices added on or attached to endoscopes or (y) any other business directly
competitive with the business of the Company on the date of termination.

 

Executive
further agrees that, during the Restricted Period, Executive shall not, directly or indirectly, either on Executive’s own
behalf or on behalf of any other individual or commercial enterprise: (i) contact, communicate, solicit or transact any business
with or assist any third party in contacting, communicating, soliciting or transacting any business with (A) any of the customers
or clients of the Company, or (B) any individual or entity who or which was within the most recent twelve (12) month period a
customer or client of Company, for the purpose of inducing such customer or client or potential customer or client to be connected
to or benefit from any competitive business or to terminate its or their business relationship with the Company; (ii) solicit,
induce or assist any third party in soliciting or inducing any individual or entity who is then (or was at any time within the
preceding six (6) an employee or full-time consultant, independent contractor or agent of Company) to leave the employment of
the Company or cease performing services for the Company; (iii) hire or engage or assist any third party in hiring or engaging,
any individual or entity that is or was (at any time within the preceding six (6) months) an employee or full-time consultant,
independent contractor or agent of the Company, or (iv) solicit, induce or assist any third party in soliciting or inducing any
other person or entity (including, without limitation, any third-party service provider or distributor) to terminate its relationship
with the Company or otherwise interfere with such relationship.

 

    	 	-10-	 

    	 

    

 

5.04       Cooperation
With Investigations/Litigation. Executive agrees, upon Company’s request, to reasonably cooperate both during and after
Executive’s employment with Company in any Company investigation, litigation, arbitration, or regulatory proceeding regarding
events that occurred during Executive’s tenure with Company. Executive will make himself reasonably available to consult
with Company’s counsel, to provide information, and to appear to give testimony. Company will reimburse Executive for reasonable
out-of-pocket expenses Executive incurs in extending such cooperation, so long as Executive provides advance written notice of
Executive’s request for reimbursement and provides satisfactory documentation of the expenses.

 

5.05       Reasonable
Restrictions/Damages Inadequate Remedy. The Parties to this agreement acknowledge that the restrictions contained in this
Article are reasonable and necessary to protect the legitimate business interests of Company and that any breach by Executive
of any provision contained in this Article may result in immediate irreparable injury to Company for which a remedy at law would
be inadequate. Accordingly, the Parties shall be entitled to temporary or permanent injunctive or other equitable relief (without
being obligated to post a bond or other collateral) in the event of any breach or threatened breach of the provisions of this
Article, in addition to any other remedy that may be available whether at law or in equity.

 

5.06       Separate
Covenants. In the event that an arbitrator or any court of competent jurisdiction shall determine that any one or more of
the provisions contained in this Article shall be unenforceable in any respect,
then such provision shall be deemed limited and restricted to the extent that the adjudicator shall deem the provision to be enforceable.
It is the intention of the parties to this Agreement that the covenants and restrictions in this Article be given the broadest
interpretation permitted by law. The invalidity or unenforceability of any provision of this Article shall not affect the validity
or enforceability of any other provision hereof. If, in any judicial or arbitration proceedings, a court of competent jurisdiction
or arbitration panel should refuse to enforce all of the separate covenants and restrictions in this Article, then such unenforceable
covenants and restrictions shall be eliminated from the provisions of this Agreement for the purpose of such proceeding to the
extent necessary to permit the remaining separate covenants and restrictions to be enforced in such proceeding.

 

5.07       Ownership
of Proprietary Rights

 

(A)       Proprietary
Rights. “Proprietary Rights” means all right, title and interest (including any copyrights, patent rights,
trademarks, servicemarks and trade names) in and to, or associated with, or arising from, any and all notes, data, reference materials,
sketches, drawings, memoranda, documentation, and any and all work product conceived, created, reduced to any medium of expression
and/or produced as part of the activities of Executive for the Company, including all written, graphical, pictorial, visual, audio,
and audiovisual elements relating thereto, software code or records in any way incorporating or reflecting any Confidential Information
and any original works of authorship, derivative works, inventions, developments, concepts, know-how, improvements, trade secrets
or ideas, whether or not fixed in a tangible medium of expression, that are conceived or developed in whole or in part by the
Executive alone or in conjunction with others, whether or not conceived or developed during regular working hours by, or in association
with, the Company that are made through the use of any Confidential Information or any of the Company’s equipment, facilities,
supplies, or trade secrets, or that relate to the Company’s business or the Company’s actual or demonstrably anticipated
research and development, or that result from any work performed by the Executive for the Company.

 

    	 	-11-	 

    	 

    

 

(B)       Ownership
of Proprietary Rights. All Proprietary Rights shall belong exclusively to the Company, and the Executive agrees to assign
and hereby assigns to the Company, all rights, title and interest throughout the world in and to all Proprietary Rights. The Executive
agrees to promptly make full written disclosure to the Company, and will hold in trust for the sole right and benefit of the Company,
all Proprietary Rights. Upon request of the Company and without any separate compensation, the Executive shall take such action
and execute and deliver such documents and instruments as may be necessary or proper to vest in the Company all right, title and
interest in and to all such Proprietary Rights. Without limiting the foregoing, the Executive further agrees that for any original
works of authorship created by the Executive, the Company shall be deemed the author thereof under the United States Copyright
Act; provided, however, that in the event and to the extent such works do not to constitute “works made for
hire” as a matter of law, the Executive agrees to irrevocably assign and transfer, and hereby irrevocably assigns and transfers
to the Company, all right, title and interest in and to such works, including but not limited to copyrights.

 

(C)       Maintenance
of Records. The Executive covenants and agrees to take commercially reasonable measures to keep and maintain adequate and
current written records of all inventions and works of authorship made by the Executive (solely or jointly with others) during
the term of the Executive’s relationship with the Company. The records may be in the form of notes, sketches, drawings,
flow charts, electronic data or recordings, laboratory notebooks, and any other format. The records will be available to and remain
the sole property of the Company at all times. The Executive agrees not to remove such records from the Company’s place
of business except as expressly permitted by the Company policy, which may, from time to time, be revised at the sole election
of the Company. The Executive agrees to return all such records (including any copies thereof) to the Company at the time of termination
of services with the Company.

 

(D)       Recordation
of Rights. The Executive covenants and agrees to assist the Company, or its designee, at the Company’s expense, in every
proper way to secure the Company’s, or its designee’s, rights in the inventions and any copyrights, patents, trademarks,
servicemarks, moral rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure
to the Company or its designee of all pertinent information and data with respect thereto, the execution of all applications,
specifications, oaths, assignments, recordations, and all other instruments that the Company or its designee shall deem necessary
in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive such rights, and in order to assign
and convey to the Company or its designee and any successors, assigns and nominees the sole and exclusive rights, title and interest
in and to such inventions, and any copyrights, patents or other intellectual property rights relating thereto. The Executive further
agrees that the obligation to execute or cause to be executed, when it is in the Executive’s power to do so, any such instrument
or papers shall continue after the termination of this Agreement until the expiration of the last such intellectual property right
to expire in any country of the world. If the Company or its designee is unable because of the Executive’s mental or physical
incapacity or unavailability or for any other reason to secure the Executive’s signature to apply for or to pursue any application
for any United States or foreign patents, copyrights, or other registrations covering inventions or works of authorship assigned
or to be assigned to the Company or its designee as above, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as the Executive’s agent and attorney-in-fact, to act for and on the Executive’s
behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the application
for, prosecution, issuance, maintenance or transfer of letters patent, copyright or other registrations thereon with the same
legal force and effect as if originally executed by the Executive. The Executive hereby waives and irrevocably quitclaims to the
Company or its designee any and all claims, of any nature whatsoever, that the Executive now or hereafter has for infringement
of any and all proprietary rights assigned to the Company or such designee.

 

    	 	-12-	 

    	 

    

 

ARTICLE
VI

MISCELLANEOUS

 

6.01       Benefit
of Agreement and Assignment. This Agreement shall inure to the benefit of Company, its affiliates and their respective successors
and assigns (including, without limitation, the purchaser of all or substantially all of the assets of Company and/or any of its
affiliates) and shall be binding upon Company and its successors and assigns. This Agreement also shall inure to the benefit of
and be binding upon Executive and Executive’s heirs, administrators, executors and assigns. Executive may not assign or
delegate Executive’s duties under this Agreement, without the prior written consent of Company.

 

6.02       Notices.
All notices, requests, demands and other communications required or permitted hereunder shall be given in writing and shall be
deemed to have been duly given (i) on the date delivered if personally delivered, (ii) upon receipt by the receiving party of
any notice sent by registered or certified mail (first-class mail, postage pre-paid, return receipt requested), (iii) by email,
or (iv) on the date targeted for delivery if delivered by nationally recognized overnight courier or similar courier service,
addressed in the case of Company to:

 

	Motus
    GI Medical Technologies Ltd.,	 	 
	1301
        East Broward Blvd

        
	 	with
    a copy which, itself, shall not constitute notice, to:
	Fort
Lauderdale, Florida 33301	 	Lowenstein
        Sandler LLP

        One
        Lowenstein Drive

	 	 	Roseland,
    NJ 07068
	Attn:
    Chief Executive Officer	 	Attn:
    Steven M. Skolnick, Esq.

 

and
in the case of Executive to:

 

	————

        ————

        ————
	 

 

    	 	-13-	 

    	 

    

 

Any
Party may notify the other party in writing of the change in address by giving notice in the manner provided in this Section 6.02.
Service of process in connection with any suit, action or proceeding (whether arbitration or otherwise) may be served on each
party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.

 

6.03       Non-Disparagement.
During the Term and at all times thereafter, Executive agrees that Executive shall not knowingly disparage, criticize or otherwise
make any derogatory statements regarding Company or its past, present and future directors, officers, shareholders, employees,
agents or products.

 

6.04       Indemnification.
The Company indemnifies Executive to the maximum extent provided in the Company’s By-Laws and organizational documents,
as currently in effect. Executive shall be entitled to coverage under the directors and officers liability insurance on terms
no less favorable to him in any respect than the coverage then being provided to any other current or former director or officer
of the Company and which the Company shall maintain with minimum coverage of $1 million.

 

6.05       Arbitration.
With the exception of the Company’s right to seek injunctive relief in a court of competent jurisdiction to enforce Article
V, any dispute or controversy arising out of or relating to this Agreement or Executive’s performance thereunder shall be
exclusively settled by arbitration before a single arbitrator to be held in Florida in accordance with the rules then in effect
of the American Arbitration Association. The decision of the arbitrator shall be final, conclusive and binding on the parties
to the arbitration. Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. The Company and
the Executive shall separately pay their own counsel fees and expenses. The arbitrator shall apply the laws of the State of Florida
with respect to interpretation, construction or enforcement of this Agreement without giving effect to the principles of conflicts
of law.

 

6.06       Entire
Agreement. This Agreement contains the entire agreement of the Parties with respect to the terms and conditions of Executive’s
employment during the Term and activities following termination of this Agreement and Executive’s employment with Company
and supersedes any and all prior agreements and understandings, whether written or oral, between the Parties with respect to the
subject matter of this Agreement. This Agreement may not be changed or modified except by an instrument in writing, signed by
both the Company and the Executive.

 

6.07.       Representation
and Warranties. Executive and Company each respectively represent and warrant to the other that (a) he/it has the legal capacity
to execute and perform this Agreement, (b) this Agreement is a valid and binding agreement enforceable against the parties according
to its terms, and (c) the execution and performance of this Agreement by him/it does not violate or conflict with the terms of
any existing agreement or understanding to which Executive or Company is a party or by which Executive or Company may be bound.

 

    	 	-14-	 

    	 

    

 

6.08       No
Attachment. Except as required by law, no right to receive payments under this Agreement shall be subject to anticipation,
commutation, alienation, sale, assignment, encumbrance, charge, pledge, or hypothecation or to execution, attachment, levy, or
similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to effect any such action shall
be null, void and of no effect; provided, however, that nothing in this Section 6.06 shall preclude the assumption of such
rights by executors, administrators or other legal representatives of Company or Executive’s estate and their assigning
any rights hereunder to the person or persons entitled thereto.

 

6.09       Source
of Payment. All payments provided for under this Agreement shall be paid in cash from the general funds of Company. The Company
shall not be required to establish a special or separate fund or other segregation of assets to assure such payments, and, if
Company shall make any investments to aid it in meeting its obligations hereunder, Executive shall have no right, title or interest
whatever in or to any such investments except as may otherwise be expressly provided in a separate written instrument relating
to such investments. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed
to create a trust of any kind, or a fiduciary relationship, between Company and Executive or any other person. To the extent that
any person acquires a right to receive payments from Company hereunder, such right, without prejudice to rights which Executives
may have, shall be no greater than the right of an unsecured creditor of Company.

 

6.10       No
Waiver. The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a continuing
waiver or as a consent to or waiver of any subsequent breach hereof.

 

6.11       Headings.
The Article and Section headings in this Agreement are for the convenience of reference only and do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the provisions hereof.

 

6.12       Validity.
The invalidity or enforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability
of any other provision or provisions of this Agreement, which shall remain in full force and effect.

 

6.13       Executive
Withholdings and Deductions. All payments to Executive hereunder shall be subject to such withholding and other Executive
deductions as may be required by law.

 

6.14       Counterparts.
This Agreement may be executed in one more counterparts, each of which shall be deemed to be an original but all of which together
will constitute one and the same instrument.

 

6.15       Agreement
to Take Actions. Each Party shall execute and deliver such documents, certificates, agreements and other instruments, and
shall take all other actions, as may be reasonably necessary or desirable in order to perform his or its obligations under this
Agreement.

 

    	 	-15-	 

    	 

    

 

6.16       Survival.
The terms of Section 4.02 and Articles V and VI of this Agreement shall survive the termination of this Agreement and Executive’s
employment hereunder.

 

6.17       Section
409A Compliance.

 

(A)       This
Agreement is intended to comply with the requirements of Section 409A of the Code (“Section 409A”) and regulations
promulgated thereunder. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A,
the provision shall be read in such a manner so that all payments due under this Agreement shall comply with Section 409A. For
purposes of section 409A, each payment made under this Agreement shall be treated as a separate payment. In no event may Executive,
directly or indirectly, designate the calendar year of payment. Notwithstanding anything contained herein to the contrary, Executive
shall not be considered to have terminated employment with Company for purposes of Section 4.02 of this Agreement unless Executive
would be considered to have incurred a “termination of employment” from Company within the meaning of Treasury Regulation
§1.409A-1(h)(1)(ii).

 

(B)       All
reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including,
where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive’s lifetime (or during
a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar
year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible
expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv)
the right to reimbursement is not subject to liquidation or exchange for another benefit.

 

(C)       Executive
acknowledges that, while the Parties endeavor to have this Agreement comply with the requirements of Section 409A, any tax liability
incurred by Executive under Section 409A is solely the responsibility of Executive.

 

6.18       Legal
Counsel. Executive represents that Company has previously recommended that Executive engage counsel to assist Executive in
reviewing this Agreement. Executive acknowledges that, prior to executing this Agreement, Executive has been given a reasonable
opportunity to review the Agreement and to consult with counsel as to its content and is entering into this Agreement freely and
voluntarily.

 

[Signatures
appear on the following page]

 

    	 	-16-	 

    	 

    

 

IN
WITNESS WHEREOF, Company and Executive have duly executed this Agreement as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	Motus GI Medical Technologies Ltd.
	 	 	 
	 	BY:	/s/
    Mark Pomeranz 
	 	Name:	Mark
    Pomeranz
	 	Title:	CEO
	 	 	 
	 	EXECUTIVE:
	 	 	 
	 	/s/ Andrew Taylor
	 	Andrew Taylor

 

    	 	-17-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]